Disruptive Pharma

Executive Summary

Disruptive Pharma is a clinical-stage pharmaceutical development company based in Stockholm, Sweden, specializing in transforming drugs with poor bioavailability into effective, patient-friendly oral solid dosage forms. Founded in 2016, the company leverages innovative drug delivery technologies to address a critical unmet need in the pharmaceutical industry: many active pharmaceutical ingredients (APIs) exhibit low oral bioavailability, limiting their therapeutic potential and patient compliance. By enabling oral administration of these challenging compounds, Disruptive Pharma aims to improve efficacy, reduce healthcare costs, and enhance the patient experience. The company's proprietary platform focuses on formulating drugs that are currently administered via injection or other routes into stable, oral solid dosage forms. While still in the pre-clinical stage, Disruptive Pharma has the potential to create significant value through partnerships with larger pharmaceutical companies seeking to reformulate their pipeline assets. The management team possesses deep expertise in drug formulation and development, positioning the company to advance its lead candidates toward clinical trials. However, as an early-stage private company, its success hinges on securing funding, completing preclinical studies, and demonstrating proof-of-concept in vivo. The company's innovative approach and focus on high-value drug reformulation make it an attractive prospect for strategic collaborations.

Upcoming Catalysts (preview)

• Q4 2026Completion of preclinical proof-of-concept studies70% success
• Q2 2027Strategic partnership with major pharma for lead candidate35% success
• Q3 2026Securing Series A financing to initiate clinical trials50% success